Oil: 'To the Moon'?

Source: Seeking Alpha, Tom Schumacher (4/13/09)

". . . we believe that the world's spare oil capacity will be gone by 2011."

The market is underweighting a potential oil supply crunch that could reignite higher prices. On the supply side, the current economic slowdown has eased significant exploration ventures. This may cause a bottleneck, as future demand, spurred by emerging market growth, outpaces supply. Looking at the converging paths of new supply coming online and future oil field decline rates, we believe that the world's spare oil capacity will be gone by 2011.

Giant oil fields, accounting for most of the world's oil production, have seen production rate declines. Concurrently, the rate of decline for smaller fields could be greater than, if not equal to, their giant brothers. New production has only served to sustain recent global production levels, and the carrot of optimism being waved in the form of alternative energy will not alleviate the burden oil carries as the world's main source of energy.

A shift is occurring between national and international oil companies. Oil production at nationals will account for most of the increases in future production. As production becomes concentrated in a small number of countries and emerging markets begin to account for greater consumption of future production, inefficiencies and supply disruptions will likely lead to volatile spikes in pricing.

M&A activity will be driven by large-cap energy names that are thirsty for additional reserves. Traditional growth will be spurred from historically non-traditional exploration sources. Large firms will look to snap up smaller cash- and credit-strapped companies. Consequently, we believe that investors will benefit from the industry's rapid pace of M&A activity.

The effects of massive stimulus packages by the U.S. and industrialized nations will likely pressure oil prices higher on two fronts—a weakening U.S. dollar and higher consumption. Given the accelerating economic decline of many OPEC countries, we believe they will be hard-pressed to increase capacity until oil reaches ~$70 per barrel. If OPEC does not reverse production cuts, growth in future supplies may fall behind a stimulus-driven recovery of demand, leading to higher oil prices.

We believe that future supply concerns have the potential to be a Trojan horse, besieging the world again with higher oil prices. It is only a matter of when, not if, oil prices move higher.

Align Technology Shares Grind 12.5% Higher after Firm Posts Record Q4 Revenue of $834.5 Million
Source: Streetwise Reports (02/04/2021)

Align Technology shares set a new 52-week high after the company announced financial results that included record FY/20 total revenues of $2.5 billion.

Small-Cap Psychedelic Wellness Company Makes First Acquisition: Ketamine Infusion Centers
Source: Streetwise Reports (02/04/2021)

DELIC aims to become a leader in psychedelic health and wellness clinics.

GW Pharmaceuticals Shares Gain 46% on $7.2 Billion Acquisition by Jazz Pharmaceuticals
Source: Streetwise Reports (02/03/2021)

Shares of GW Pharmaceuticals reached a new 52-week high after the company reported it agreed to be acquired by Jazz Pharmaceuticals in a combination cash and stock deal for $220.00 per share.

Shares of Cassava Sciences traded 207% higher after the firm provided an interim analysis from an ongoing study demonstrating that simufilam improves cognition and behavior in mild-to-moderate Alzheimer's disease patients.

Viela Bio Shares Rise 52% on $3.05 Billion Buyout by Horizon Therapeutics
Source: Streetwise Reports (02/01/2021)

Shares of Viela Bio traded higher after it was announced that the company entered into a definitive agreement to be acquired by Horizon Therapeutics for $53.00 per share.

Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, announced that it has established a clinical research program for the treatment of stroke focused on AP-188 (DMT), a known psychedelic compound. Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.